Skip to main content

Correction to: MicroRNA-214-3p inhibits proliferation and cell cycle progression by targeting MELK in hepatocellular carcinoma and correlates cancer prognosis

The Original Article was published on 07 November 2017

Correction to: Cancer Cell Int (2017) 17:102 https://doi.org/10.1186/s12935-017-0471-1

After publication of the original article [1] it was noted that the author details and affiliations of this manuscript contained minor errors in the institution addresses.

The correct affiliations for each of the authors are listed below:

Yue Li—Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China.

You Li—College of Life Science and Technology, Guangxi University, Nanning 530004, Guangxi Province, China.

Yao Chen—Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, Guangdong Province, China.

Qian Xie—Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, Guangdong Province, China.

Ningning Dong—Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, Guangdong Province, China.

Yanjun Gao—Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, Guangdong Province, China.

Huan Deng—Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, Guangdong Province, China.

Chunhua Lu*—College of Life Science and Technology, Guangxi University, Nanning 530004, Guangxi Province, China.

Suihai Wang*—Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, Guangdong Province, China.

Reference

  1. Li Y, Li Y, Chen Y, Xie Q, Dong N, Gao Y, Deng H, Lu C, Wang S. MicroRNA-214-3p inhibits proliferation and cell cycle progression by targeting MELK in hepatocellular carcinoma and correlates cancer prognosis. Cancer Cell Int. 2017;17(1):102. https://doi.org/10.1186/s12935-017-0471-1.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Chunhua Lu or Suihai Wang.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, Y., Li, Y., Chen, Y. et al. Correction to: MicroRNA-214-3p inhibits proliferation and cell cycle progression by targeting MELK in hepatocellular carcinoma and correlates cancer prognosis. Cancer Cell Int 18, 55 (2018). https://doi.org/10.1186/s12935-018-0556-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12935-018-0556-5